Coccolini F, Catena F, Manfredi R, Montori G, Manegold JE, Ansaloni L. Value of neoadjuvant chemotherapy in advanced ovarian cancer. World J Obstet Gynecol 2015; 4(3): 64-67 [DOI: 10.5317/wjog.v4.i3.64]
Corresponding Author of This Article
Federico Coccolini, MD, General and Emergency Surgery Department, Papa Giovanni XXIII Hospital, P.zza OMS 1, 24128 Bergamo, Italy. federico.coccolini@gmail.com
Research Domain of This Article
Surgery
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Obstet Gynecol. Aug 10, 2015; 4(3): 64-67 Published online Aug 10, 2015. doi: 10.5317/wjog.v4.i3.64
Value of neoadjuvant chemotherapy in advanced ovarian cancer
Federico Coccolini, Fausto Catena, Roberto Manfredi, Giulia Montori, Jennifer E Manegold, Luca Ansaloni
Federico Coccolini, Roberto Manfredi, Giulia Montori, Luca Ansaloni, General and Emergency Surgery Department, Papa Giovanni XXIII Hospital, 24128 Bergamo, Italy
Fausto Catena, Emergency Surgery Department, Ospedale Maggiore, 43100 Parma, Italy
Jennifer E Manegold, David Geffen School of Medicine, University of California, Los Angeles, CA 90073, United States
Author contributions: Coccolini F, Catena F and Ansaloni L analyzed data, drafted the manuscript and gave final approval; Manfredi R, Montori G and Manegold JE critically revised the manuscript, gave final approval.
Conflict-of-interest statement: All authors declare to have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Federico Coccolini, MD, General and Emergency Surgery Department, Papa Giovanni XXIII Hospital, P.zza OMS 1, 24128 Bergamo, Italy. federico.coccolini@gmail.com
Telephone: +39-35-2673486 Fax: +39-35-2674963
Received: February 10, 2015 Peer-review started: February 13, 2015 First decision: March 6, 2015 Revised: March 20, 2015 Accepted: June 18, 2015 Article in press: June 19, 2015 Published online: August 10, 2015 Processing time: 187 Days and 20 Hours
Abstract
Data regarding the role of neoadjuvant chemotherapy (NACT) are not definitive. Several randomized trials and meta-analyses demonstrate that this chemotherapy regimen decreases the morbidity and mortality rates and increases complete cytoreduction rates. If combined with hyperthermic intraperitoneal chemotherapy (HIPEC), NACT could potentially further improve upon these already promising results. Moreover the use of NACT could help in evaluating the chemo-sensitivity of the cancer, thus preventing unnecessary HIPEC procedures in chemo-resistant patients. NACT should definitely be considered as a preferred regimen in the management of advanced ovarian cancer, especially in association with cytoreductive surgery + HIPEC procedure in the context of a multidisciplinary team management in an experienced cancer centre.
Core tip: Data about the use of neoadjuvant chemotherapy in advanced ovarian cancer are not sufficient to support its extensive application. However encouraging results came from the existing studies. Future well designed studies are needed to clarify some aspects of this chemotherapy regimen and its association with the other form of pharmacological and surgical therapy.
